GLYNASE PRESTAB Rx
Generic Name and Formulations:
Glyburide, micronized 1.5mg, 3mg, 6mg; scored tabs.
Indications for GLYNASE PRESTAB:
Adjunct to diet and exercise in type 2 diabetes.
Initially 1.5–3mg daily with breakfast. Debilitated: initially 0.75mg daily with breakfast. Increase by 1.5mg at weekly intervals if needed per blood glucose. Maintenance: 0.75–12mg daily in single or divided doses (consider divided doses above 6mg daily); max 12mg daily.
Initially 0.75mg daily with breakfast.
Diabetic ketoacidosis, with or without coma. Type 1 diabetes. Concomitant bosentan.
Increased risk of cardiovascular mortality. Impaired renal or hepatic function. Stress. Secondary failure may occur with extended therapy. Discontinue if jaundice or persistent rash occurs. G6PD deficiency; consider non-sulfonylurea alternative. Monitor urine, blood glucose, and glycosylated hemoglobin. Retitrate if transfer from other glyburide containing or hypoglycemic agents (see full labeling). Elderly, debilitated, malnourished, adrenal or pituitary insufficiency, severe/prolonged exercise: increased risk of hypoglycemia. Pregnancy (Cat.B): consider using insulin instead; if glyburide needed, discontinue ≥2 weeks before delivery date. Nursing mothers: not recommended.
Elevated liver enzymes with concomitant bosentan (see Contraindications). Increased risk of hypoglycemia with concomitant alcohol or other hypoglycemics. Potentiated by NSAIDs, alcohol, highly protein bound drugs, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, MAOIs, β-blockers. Antagonized by diuretics, steroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, niacin, sympathomimetics, calcium channel blockers and isoniazid. May be potentiated by ciprofloxacin, oral miconazole. Administer glyburide >4hrs prior to colesevelam. Disulfiram-like reaction with alcohol (rare). Monitor for 2 weeks if transferring from chlorpropamide.
Sulfonylurea (2nd generation).
Hypoglycemia, cholestatic jaundice (rare), nausea, epigastric fullness, heartburn, allergic skin reactions, photosensitivity, blood dyscrasias, hepatic porphyria, hyponatremia.
PresTab 1.5mg—100; 3mg—100, 500, 1000; 6mg—100, 500
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Effect of Infant Feeding Practices and Gut Microbiota on Overweight in First Year
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Cleared Blood Glucose Monitor Systems Not Always Accurate
- CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
- Vascular Mortality Declining in Adults With Diabetes in the United States